Search Results
Your search for ,OUr matches 10645 pages
Showing 5001 - 5050How Effective Is Talimogene Laherparepvec Injection in Metastatic Melanoma?
Injection of a genetically modified virus that induces the body’s own immune cells to attack metastatic melanoma effectively treated almost 40% of patients with tumors that could not be surgically removed, according to findings published by Louie et al in the Journal of the American...
ASCO Clinical Cancer Advances 2019 Names Advance of the Year: Progress in Treating Rare Cancers
Over the past year, major research advances provided new treatment options for patients with rare, difficult-to-treat cancers. In recognition of these achievements, ASCO named “Progress in Treating Rare Cancers” as the Advance of the Year. To continue the forward momentum, ASCO also...
Cost-Effectiveness Analysis of Gene-Expression Profiling Assay in Breast Cancer
A new report published by Wang et al in JNCCN—Journal of the National Comprehensive Cancer Network found that using Oncotype DX—the most commonly used test for predicting the benefit of adjuvant chemotherapy to reduce the risk of disease recurrence—is not...
Polymorphisms in Pattern Recognition Receptors as Predictors of Oxaliplatin Benefit in Colorectal Cancer
In a study reported in the Journal of the National Cancer Institute, Gray et al found that constitutional loss of function single-nucleotide polymorphisms in the pattern recognition receptors FPR1, TLR3, and TLR4 were not associated with preferential benefit of oxaliplatin in colorectal cancer. As...
Oncology Pioneer V. Shanta, MD, Has Long Championed Access to Quality Cancer Care
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, interviewed V. Shanta, MD, an internationally renowned oncologist and Chairperson of the Cancer Institute in Adyar, Chennai, India. Dr. Shanta has been with the Institute since 1955, holding several positions...
Hastening the Development of Novel Therapies for Peripheral T-Cell Lymphomas
Peripheral T-cell lymphomas (PTCLs) make up a small fraction of all non-Hodgkin lymphomas—just 15%—in the United States.1 Although rare in the United States, the incidence of PTCL is common across Asia, the Caribbean, and sub-Saharan Africa. Although the reason for such global variation in PTCL is...
Community Oncology Alliance Elects New Officers and Board Members
THE COMMUNITY Oncology Alliance (COA) recently announced that Michael Diaz, MD, a practicing medical oncologist at Florida Cancer Specialists & Research Institute, has been elected President of COA. His 1-year term began on January 1, 2019. In addition, Kashyap Patel, MD, a practicing...
Genomic Classifier for Luminal Androgen Receptor Triple-Negative Breast Cancer
TRIPLE-NEGATIVE breast cancer is a heterogeneous disease that comprises several subtypes, which may respond differently to therapy. Breast cancer researchers at the Mayo Clinic are developing a novel genomic signature that may improve the identification of the luminal androgen receptor vs basal...
Addition of Atezolizumab to Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: IMpassion130 Trial
AS REPORTED in The New England Journal of Medicine by Peter Schmid, MD, PhD, of the Barts Cancer Institute, Queen Mary University of London, and colleagues, the phase III IMpassion130 trial has shown that the addition of atezolizumab to nanoparticle albumin-bound (nab)-paclitaxel significantly...
Changing Perceptions on Surgical Intervention for Geriatric Patients With Cancer: Role of the SIOG Surgical Task Force
Surgery is an integral part of treatment of elderly patients with solid malignancies. The times we are living in will be remembered by health-care providers for the significant “contradictions” in the medical and surgical care of elderly patients with cancer. On the one hand, it has been...
Preventing Locoregional Recurrence of Breast Cancer Should Not Deter Efforts to Decelerate Therapy
“SURGEONS AND radiation oncologists are obsessed with locoregional recurrence of breast cancer,” Monica Morrow, MD, FASCO, remarked at the 2018 Lynn Sage Breast Cancer Symposium, Chicago. Working to prevent locoregional recurrence, “even if it may not be the major threat to mortality, is...
Risk of Local Recurrence in Breast Cancer: Impact of Molecular Subtype and Surgical Approach
THE RISK of local recurrence in breast cancer “does not differ substantially based on the operation we perform, but it does differ substantially by subtype,” Tari A. King MD, FACS, stated at the 2018 Lynn Sage Breast Cancer Symposium in Chicago.1 At 10-year follow-up, Dr. King reported, local...
$30 Million Granted to MD Anderson Scientists for Various Research Investigations
THE UNIVERSITY of Texas MD Anderson Cancer Center was awarded $30 million from the Cancer Prevention and Research Institute of Texas to support research, core facilities, recruitment, and prevention efforts. An additional $19.9 million was awarded to a company co-founded by MD Anderson to support...
BEAT AML Umbrella Trial: Bringing Personalized Medicine to Acute Myeloid Leukemia
THE MULTIARM, multicollaborative BEAT AML umbrella trial demonstrated the feasibility of using next-generation sequencing to assign treatment tailored to individual genomics of elderly patients with acute myeloid leukemia (AML) within 7 days. This may prove to be a major advance, since typically...
Oxybutynin: A Novel Option for Managing Hot Flashes?
OXYBUTYNIN, AN ANTICHOLINERGIC drug approved for the treatment of overactive bladder, reduced the frequency and intensity of hot flashes in women who were suffering frequent hot flashes, including breast cancer survivors who were receiving tamoxifen or aromatase inhibitors. These results of the...
HPV Vaccination Rates in Younger Adolescents
Only about 16% of U.S. adolescents have been fully vaccinated against human papillomavirus (HPV) by the time they turn 13, despite national recommendations that call for vaccination at 11 to 12 years of age. These findings, published by Bednarczyk et al in the Journal of Infectious Diseases,...
Role of Adjuvant Capecitabine in Triple-Negative Breast Cancer
ADJUVANT CAPECITABINE added to standard neoadjuvant chemotherapy failed to significantly improve disease-free or overall survival in patients with early triple-negative breast cancer in the large phase III CIBOMA/2004-01_GEICAM/2003-11 (CIBOMA/GEICAM) trial.1 However, extended treatment with...
How to Save Billions on Cancer Care Costs: The Potential of Value-Based Prescribing in Oncology
IT IS TIME for value-based prescribing—the reduction of prescribing costs using basic pharmacologic principles—to be tested and deployed in oncology. The savings are real and there for the taking. If you are concerned about the high costs in cancer care, here is a chance to get maximum value for...
Low-Dose Tamoxifen Halves Breast Cancer Risk in Women With Preinvasive Breast Lesions
A VERY LOW DOSE of tamoxifen—5 mg/d, given for 3 years rather than 5 years—halved the risk of breast cancer recurrence or new lesions over placebo in women with breast intraepithelial neoplasia, without producing the usual toxicities seen with the standard dose, Italian researchers reported at the...
Over 40 Medical Organizations Call for an End to the Government Shutdown
Forty-six medical advocacy organization and professional societies have called on President Donald Trump, Speaker of the House Nancy Pelosi, Senate Majority Leader Mitch McConell, Senate Minority Leader Chuck Schumer, and House Minority Leader Kevin McCarthy to end the government shutdown and, in...
Newly Defined Subtypes of B-Cell Acute Lymphoblastic Leukemia
Investigators have identified multiple new subtypes of the most common childhood cancer, B-cell acute lymphoblastic leukemia (ALL)—research that has the potential to improve the diagnosis and treatment of high-risk patients. Researchers used integrated genomic analysis, including...
Oncologist Survey on Knowledge About LGBTQ Patients With Cancer
In a national survey of oncologists reported in the Journal of Clinical Oncology, Schabath et al found that whereas oncologists tended to have limited knowledge regarding lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) patient health and cancer needs, they indicated high interest ...
Outcomes With AHCT Consolidation in Younger Patients With Mantle Cell Lymphoma in the Rituximab Era
In a retrospective study reported in the Journal of Clinical Oncology, Gerson et al found evidence that autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy was associated with a progression-free survival benefit in patients with mantle cell lymphoma aged...
MD Anderson President Emeritus, John Mendelsohn, MD, Dies at Age 82
John Mendelsohn, MD, President Emeritus of The University of Texas MD Anderson Cancer Center, died of glioblastoma on January 7, 2019, at his home in Houston at age 82. He was an internationally acclaimed leader in the field of medicine and scientist whose research helped pioneer a new type of...
Patient Navigation Program Reduces Time to Cancer Treatment
The Global Cancer Institute recently announced the results of its Patient Navigation Program in Mexico City. The average time to referral before the program’s inception was 5 months, but the implementation of patient navigators reduced that average to 7 days. These findings were published by Yanin...
A Tribute to Arti Hurria, MD, FASCO, a Leader in Geriatric Oncology
The oncology community is deeply saddened by the untimely passing of Arti Hurria, MD, FASCO, a nationally regarded expert and advocate for elderly patients with cancer. Dr. Hurria died on November 7, 2018, in a traffic accident. At the time of her tragic death, Dr. Hurria was Director of the City...
Huntsman Cancer Institute Announces Construction of Proton Therapy Center
The Huntsman Cancer Institute (HCI) at the University of Utah recently began construction on a proton therapy center. The $31 million, 7,450 square-foot addition to the HCI’s Cancer Hospital will be the first proton therapy center in the Mountain West. The new center will be named in honor of...
A Visionary in Lymphoma, Bertrand Coiffier, MD, PhD, Dies at 71
Internationally renowned lymphoma expert Bertrand Coiffier, MD, PhD, died on January 2, 2019. He was 71. Dr. Coiffier published more than 500 papers and book chapters that garnered more than 50,000 literature citations, placing him among the top 1% of the most influential researchers globally. His ...
Remnants of Cancer Remain, but Demons Are Now Gone
In the summer of 2002, I was a physically active 17-year-old boy on the cusp of adulthood. I was about to enter my senior year in high school, and like other teens my age, I was excited about college and the promise of the undreamed-of opportunities that lay ahead. At first, the lethargy I was...
Established, Modifiable Cancer Risk Factors
According to a new American Cancer Society report published by Susan M. Gapstur, PhD, MPH, American Cancer Society Senior Vice President of Behavioral and Epidemiology Research, and colleages in CA: A Cancer Journal for Clinicians, the highest priority in a national cancer control plan is the...
FDA Approves Cabozantinib in Previously Treated Hepatocellular Carcinoma
On January 14, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) tablets for patients with hepatocellular carcinoma who have been previously treated with sorafenib. The FDA’s approval of this oral tyrosine kinase inhibitor was based on the results of the phase III...
Findings From ASCO’s Second National Cancer Opinion Survey
Despite a recent study showing that patients with cancer who chose alternative therapies over conventional cancer treatment have a higher risk of death, nearly 4 in 10 Americans believe cancer can be cured by alternative remedies alone, according to the results of ASCO’s 2018 National Cancer...
Clinical Trial Commences on Personalized Vaccine in Kidney Cancer
Researchers at the Dana-Farber Cancer Institute in Boston are testing a first-of-its-kind personalized cancer vaccine combined with an immunotherapy drug, with the aim of improving outcomes for patients with kidney cancer who are at high risk of recurrence after surgery. A two-pronged approach to...
Novel Treatments in Newly Diagnosed Multiple Myeloma, Part 1
Here is an update on several different studies focusing on novel treatments for patients with newly diagnosed multiple myeloma presented at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition. Featured therapeutics include daratumumab plus lenalidomide and dexamethasone, ...
ASCO to Convene Global Summit on Latest Innovations in Technology and Cancer
Advances in medicine and technology are emerging faster than ever before. To harness this momentum, ASCO is convening Breakthrough: A Global Summit for Oncology Innovators, a new meeting focused on the intersection of medicine, scientific discovery, and innovations in technology. The inaugural...
Improved Data Sharing Through CancerLinQ Certification Continues to Expand
The number of electronic health record (EHR) systems joining with CancerLinQ® to facilitate information sharing continues to grow. CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, announced this past month that Varian’s ARIA Oncology Information System (OIS) is the next Electronic...
Lori J. Pierce, MD, FASTRO, FASCO, Elected ASCO President for 2020–2021 Term
ASCO has elected Lori J. Pierce, MD, FASTRO, FASCO, a long-time member and volunteer, to serve as its President for the term beginning in June 2020. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2019. Six new members were also elected to the ASCO Board of ...
Common Markers of Tumor Hypoxia Found Across Cancer Types
Unlike healthy tissues, tumors thrive in low-oxygen environments, often acquiring the ability to resist treatment and spread to other sites in the body. Despite being a well-known cause of therapy resistance and metastasis, the impact of hypoxia on tumor cells is poorly understood. Researchers have ...
Comorbidities and Cancer Clinical Trial Enrollment
Patients diagnosed with cancer who also have other illnesses or conditions, such as hypertension, asthma, or a prior cancer, are less likely to talk with their health-care provider about a cancer clinical trial, are less likely to be offered to join a clinical trial, and are ultimately less likely...
FDA Approves Cabozantinib for Previously Treated Hepatocellular Carcinoma
On January 14, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) tablets for patients with hepatocellular carcinoma who have been previously treated with sorafenib. The FDA’s approval of cabozantinib was based on results from the phase III CELESTIAL trial....
Al Identifies Features of Tumor Cells in High-Risk Ovarian Cancer
Scientists have developed a new test that scans the shapes of tumor cells to select women with especially aggressive ovarian cancer. A team at The Institute of Cancer Research (ICR), London, created an artificial intelligence (AI) tool that looks for clusters of cells within tumors with misshapen...
Role of Donor Race in Liver Transplant Outcomes in African American Patients With Hepatocellular Carcinoma
Among African American adults undergoing liver transplant to treat hepatocellular carcinoma, patients whose organ donor was also African American lived significantly longer than those with a racially unmatched donor, report authors of a new study using national data. Their findings were published...
Patient Navigation Program Reduces Time to Treatment in Patients With Cancer
Global Cancer Institute recently announced the results of its Patient Navigation Program in Mexico City. The average time to referral before the program’s inception was 5 months, but the implementation of patient navigators reduced that average to 7 days. These findings were published by ...
2018 Young-Onset Colorectal Cancer Survey Report Covers Disease Stage at Diagnosis and More
Nearly three-quarters of patients with young-onset colorectal cancer are diagnosed with an advanced stage of the disease, a significantly higher percentage than has been reported for their more mature peers, according to a report from the Colorectal Cancer Alliance. The findings of...
Quality of Life and Patient- and Clinician-Reported Cumulative Toxicity
New research has found that quality of life for people with cancer is reduced by an accumulation of low-level toxicities just as much as it is from high-level adverse events. Additionally, patient-reported outcomes were more likely to reflect the impact on a patient’s physical well-being than ...
Negative Colonoscopy and Long-Term Risk of Colorectal Cancer
Ten years after a negative colonoscopy, patients who were rescreened for colorectal cancer had a lower risk of being diagnosed with and were less likely to die from colorectal cancer compared with those who did not undergo colorectal cancer screening, according to a study published by Lee et al...
New Study Examines Orphan Drug Exclusivity and Pricing
A new report commissioned by the National Organization for Rare Disorders (NORD) and published by the IQVIA Institute demonstrates that the 7-year market exclusivity granted to drugs designated under the Orphan Drug Act of 1983 for rare diseases is working as intended. In nearly every case, orphan...
ASCO and ESMO Publish Joint Assessment of Their Value Frameworks
TO BETTER UNDERSTAND the performance characteristics of ASCO’s Value Framework Net Health Benefit Score version 2 (ASCO-NHB v2)1 and the European Society for Medical Oncology’s (ESMO’s) Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1),2 ASCO and ESMO undertook a joint project to...
IASLC Announces Dave Mesko, MBA, as New Chief Executive
THE INTERNATIONAL Association for the Study of Lung Cancer (IASLC) has announced Dave Mesko, MBA, as its new Chief Executive Officer. Mr. Mesko replaces Fred R. Hirsch, MD, PhD, who left IASLC after his 5-year term ended on October 31, 2018. Mr. Mesko will be primarily responsible for the overall ...
For Maria Papaleontiou, MD, Research Holds the Key to Improving Care of Patients With Thyroid Cancer
Maria Papaleontiou, MD, whose research interests focus on the complex issues surrounding the management of thyroid cancer and thyroid disease in general, was born on Cyprus, a small island nestled in the azure waters of the Mediterranean Sea. She recently spoke with The ASCO Post about her life and ...
